Rotterdam, the Netherlands (24 October 2025) – IMCD Group (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, will exhibit at CPHI Frankfurt 2025 from 28 to 30 October, where its experts will unveil a portfolio of greener, smarter, patient-centric solutions designed to meet the evolving demands of the pharmaceutical industry.
At this year’s event, IMCD will highlight how its technical expertise, sustainable innovation, and collaborative approach are helping customers accelerate development and deliver better outcomes for patients.
Showcasing a curated selection of formulations, these concepts deliver tangible solutions to the pressing challenges in pharmaceutical development today. Concepts at the booth will sit under three key themes:
- Greener: Solutions that deliver sustainability across the pharmaceutical value chain. From sourcing eco-friendly excipients to promoting energy-efficient manufacturing processes. These concepts reduce environmental impact without compromising performance.
- Smarter: Leveraging its global network of technical centres and formulation experts, IMCD delivers intelligent solutions that solve complex challenges – including solubility enhancement, modified release, and taste masking. Attendees will discover innovative prototypes such as dual-layer tablets, high-load capsules, and advanced coating systems.
- Patient-centric: Formulation concepts designed with the end-user in mind. Whether it’s improving compliance through palatable paediatric formats or enhancing bioavailability for chronic therapies, IMCD will showcase patient-focused solutions that are safer, more effective, and easier to take.
At the booth, IMCD experts will present six innovative concepts, each demonstrating the company’s ability to combine regulatory insight with formulation excellence to support the rapid development of high-value therapies:
- Apixaban coated tablet – A more sustainable alternative to traditional roller compaction. The direct compression formulation reduces manufacturing steps, energy use, and cleaning, while maintaining comparable performance to the originator.
- Apremilast ointment – A novel, more patient-friendly topical treatment concept for psoriasis that enhances API solubility and skin permeation, offering a non-greasy, easy-to-apply formulation free from the side effects of oral therapy.
- Caffeine SR effervescent tablet – A dual-release concept combining immediate and sustained caffeine delivery for long-lasting energy without the “crash,” with taste masking and effervescent convenience that promote hydration and compliance.
- Ginkgo coated tablet – A direct compression, once-a-day liposomal ginkgo biloba tablet that improves absorption, ensures stability, and delivers performance in a small, easy-to-swallow format.
- Terbinafine film forming solution – A transparent, water-resistant film that provides prolonged antifungal action with a pleasant, non-tacky feel, for an advanced, patient-friendly approach to treating athlete’s foot.
- Mucoadhesive gel platform – A versatile platform for targeted, patient-centric drug delivery across oral, buccal, vaginal, and other mucosal routes, extending retention time and offering new opportunities for differentiation and patient comfort.
More information are available on our dedicated page here.
Chhanda Kapadia, Group Director, Technical Services, IMCD Pharmaceuticals, comments: “Our presence at CPHI reflects our commitment to co-creating solutions that are not only innovative but also more sustainable and patient focused. They are a first-class example of our globally connected network of technical laboratories. We are looking forward to showcasing these innovations and engaging with partners and customers to explore how we can shape the future of healthcare together”.
IMCD invites visitors to Booth 8.0S36 to meet its technical experts and explore how its tailored solutions can help bring better medicines to market.
IMCD Laboratory in Cologne, Germany (photo: IMCD)
IMCD booth at CPHI Milan 2024 (photo: IMCD)
About IMCD Group
IMCD Group, headquartered in Rotterdam, The Netherlands, is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. A strong, innovative business partner and solutions provider for producers of consumer, industrial and durable goods in multiple business sectors: Advanced Materials, Beauty & Personal Care, Coatings & Construction, Food & Nutrition, Home Care and Industrial & Institutional Care (I&I), Industrial Solutions, Lubricants & Energy, and Pharmaceuticals.
In partnership with our suppliers, we offer a broad and deep product portfolio. With our over 80 application laboratories across 60 countries, we co-create formulations and offer ’Sustainable Solutions’ that allow our business partners to make products with a positive impact on the world of today, and tomorrow. Our teams focus on providing commercial and operational excellence, using the best digital and logistics tools available to create a world of opportunity for our partners.
In 2024, with over 5,100 employees, IMCD realised revenues of EUR 4,728 million. IMCD N.V.’s shares are traded at Euronext Amsterdam (symbol: IMCD) and are included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.
For further information, please visit www.imcdgroup.com
Media contact
IMCD Media Centre
IMCD Group
Muriel Werlé
Group Communications Director
IMCD Pharmaceuticals
Eleanor Dampier
Global Communications & Marketing Director, Pharmaceuticals & UK
IMCD Germany
Caren Hassmann
Head of Marketing & Communications, Germany
